The size of the Global Neurotherapeutics Market is estimated to grow at a healthy rate from 2019 to 2024.
Neurologic disorders are defined as a change in the function of a nervous system. These are mainly caused due to structural change in the activity of the spinal cord, brain, and other nerves. These disorders are classified into three type’s namely Central nervous system disorders, Peripheral nervous system disorders, Autonomous nervous system disorders. These disorders involve progressive deterioration in mental and physical capabilities which disrupts the patient and patient’s, family. Genetic disorders, brain injury, infections, congenital health problems, and other traumas cause a change in brain activity which leads to various diseases such as Parkinson’s, neurological cancers, Alzheimer’s, Huntington’s disease, epilepsy, etc. So, Neurotherapeutics is used for the treatment of traumas causing diseases. Some of the neurotherapeutic products that are in the development phase include MEM 3454, NS2330, 189254, MKC-231, IL-13-PE38, 737004, SLV308, CEP 1347, KW-6002, MT 100, MT 300, Phosiphen, and BIBN4096 BS.
The major factors that are driving the growth of the Neurotherapeutics market are rise in the geriatric population, increasing R&D expenditure, increasing Health care expenditures, a better understanding of the nature of neurologic diseases. As an increasing number of the aged population are more susceptible to brain disorders. Therefore, the rise in the aging population and life expectancy of the people will increase the global neurotherapeutics market.
The factors that are challenging the growth of the market are restrictions by regulatory bodies, lack of proper reimbursement policy, and lack of awareness in some developing countries.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 - 2024 |
|
Segments Covered |
By Treatment, Disorders, Distribution Channels and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Abbott Laboratories, Inc., Becton Dickinson And Company, Novartis AG, Pfizer, Inc., Johnson & Johnson, Biogen, Inc., GlaxoSmithKline, Inc., AstraZeneca Plc, Sanofi-Aventis, Spiegelberg, Stryker, Covidien, Medtronic, GE Healthcare and Merck & Co. |
This research report on the Global Neurotherapeutics Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024.
Neurotherapeutics Market Analysis - By Treatment:
Neurotherapeutics Market Analysis - By Disorders:
Neurotherapeutics Market Analysis - By Distribution channels:
Regional Analysis:
North America has the highest share in the market followed by Europe and Asia-Pacific due to the presence of top market players and also major technological advancements. Asia-Pacific is an emerging market due to many countries in this region are on the brink of strong economic growth (healthcare infrastructure, health facility up-gradation, and product expansion). These countries include Japan, China, India, Malaysia, and Australia
Key companies leading the Global Neurotherapeutics Market profiled in the report are:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Neurologic Drugs
5.1.2.1 Oral Administration
5.1.2.2 Injections
5.1.2.3 Others
5.1.3 Neurologic Devices
5.1.3.1 Electroconvulsive Therapy (ECT)
5.1.3.2 Vagus Nerve Stimulation (VNS)
5.1.3.3 Transcranial magnetic stimulation
5.1.3.4 Deep Brain Stimulator
5.1.3.5 Others
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Disorders
5.2.1 Introduction
5.2.2 Central Nervous system disorder
5.2.3 Peripheral Nervous system disorder
5.2.4 Autonomous Nervous system disorder
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Distribution Channels
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Neurotherapeutic center
5.3.4 Clinical Research organisations
5.3.5 Clinics
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.3.3 By Disorders
6.1.3.4 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.4.3 By Disorders
6.1.4.4 By Distributional Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.1.5.3 By Disorders
6.1.5.4 By Distribution channels
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Becton
8.3 Novartis AG
8.4 Dickinson and Company
8.5 Pfizer
8.6 Johnson & Johnson
8.7 Biogen
8.8 Glaxosmithkline
8.9 AstraZeneca
8.10 Sanofi Aventis
8.11 Spiegelberg
8.12 Covidien
8.13 Medtronic
8.14 GE Health Care
8.15 Merck & Co
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
